MCID: PSD088
MIFTS: 37

Pseudobulbar Affect

Categories: Rare diseases, Mental diseases

Aliases & Classifications for Pseudobulbar Affect

MalaCards integrated aliases for Pseudobulbar Affect:

Name: Pseudobulbar Affect 53
Emotional Lability 53 29 6
Involuntary Emotional Expression Disorder 53 73
Pathological Crying and Laughing 53
Emotional Incontinence 53
Mood Swings 73
Pba 53

Classifications:



External Ids:

Summaries for Pseudobulbar Affect

NIH Rare Diseases : 53 Pseudobulbar affect (PBA) is a condition characterized by episodes of sudden, uncontrollable and inappropriate episodes of crying or laughing. The condition can be embarrassing and disruptive to daily life. It typically occurs in people with certain neurological conditions or injuries that affect the way the brain controls emotion. It is common in stroke survivors and people with conditions such as dementia, multiple sclerosis, Lou Gehrig’s disease (ALS) and traumatic brain injury. PBA is thought to affect more than one million people in the United States. The goal of treatment is to reduce the severity and frequency of emotional outbursts. Treatment may include the use of antidepressants and/or a combination of dextromethorphan and quinidine.

MalaCards based summary : Pseudobulbar Affect, also known as emotional lability, is related to childhood-onset cerebral x-linked adrenoleukodystrophy and kuru, and has symptoms including nervousness, mental and behavioral signs and symptoms and demoralization and apathy. An important gene associated with Pseudobulbar Affect is CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6). The drugs Diazepam and Droperidol have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone.

Wikipedia : 76 Pseudobulbar affect (PBA), or emotional incontinence, is a type of emotional disturbance characterized... more...

Related Diseases for Pseudobulbar Affect

Graphical network of the top 20 diseases related to Pseudobulbar Affect:



Diseases related to Pseudobulbar Affect

Symptoms & Phenotypes for Pseudobulbar Affect

UMLS symptoms related to Pseudobulbar Affect:


nervousness, mental and behavioral signs and symptoms, demoralization and apathy, other signs and symptoms involving emotional state, signs and symptoms involving emotional state, pregnancy mood swing

Drugs & Therapeutics for Pseudobulbar Affect

Drugs for Pseudobulbar Affect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
2
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Acetylcholine Approved Phase 4 51-84-3 187
5
Guanfacine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 29110-47-2 3519
6 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 979-32-8
7
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
8
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
9
Lorazepam Approved Phase 4 846-49-1 3958
10
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
12
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 99-66-1 3121
13
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-28-2 5757
15
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
16
Biperiden Approved, Investigational Phase 4 514-65-8 2381
17
Polyestradiol phosphate Approved Phase 4,Phase 2,Not Applicable 28014-46-2
18
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2 56-54-2 441074
19
rituximab Approved Phase 4,Phase 3 174722-31-7 10201696
20
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
21
Sertraline Approved Phase 4 79617-96-2 68617
22
Rivastigmine Approved, Investigational Phase 4,Phase 1 123441-03-2 77991
23
Ziprasidone Approved Phase 4 146939-27-7 60854
24
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
25
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
26
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
27
Ketamine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 6740-88-1 3821
28
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
29
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
30
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 1 104632-26-0 59868 119570
31
Etanercept Approved, Investigational Phase 4 185243-69-0
32
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
33
Acetaminophen Approved Phase 4 103-90-2 1983
34
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
35
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
36
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
37
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
38
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
39
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
40
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
41
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
42
Promethazine Approved, Investigational Phase 4 60-87-7 4927
43
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
44
Naltrexone Approved, Investigational, Vet_approved Phase 4,Early Phase 1 16590-41-3 5360515
45
Methamphetamine Approved, Illicit Phase 4,Phase 1 537-46-2 10836
46
Oxytocin Approved, Vet_approved Phase 4,Early Phase 1 50-56-6 439302 53477758
47
Dextromethorphan Approved Phase 4,Phase 3,Phase 2 125-71-3 5360696 5362449
48
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
49
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
50
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010

Interventional clinical trials:

(show top 50) (show all 576)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
2 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4 Midazolam Mylan;Lorazepam Mylan;Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
3 Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty Unknown status NCT01616342 Phase 4
4 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
5 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
6 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
7 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years Completed NCT01362439 Phase 4 Paliperidone ER
8 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia Completed NCT00757705 Phase 4 Paliperidone ER
9 Milnacipran for Chronic Pain in Knee Osteoarthritis Completed NCT01510457 Phase 4 Milnacipran;Placebo
10 A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia Completed NCT01577160 Phase 4 Paliperidone ER
11 Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia Completed NCT01726335 Phase 4 Risperidone prolonged release
12 Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants Completed NCT01387542 Phase 4 Paliperidone extended release (ER)
13 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia Completed NCT00761189 Phase 4 Paliperidone
14 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission Completed NCT00761579 Phase 4 Paliperidone
15 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
16 Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants Completed NCT00784238 Phase 4 Paliperidone
17 A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia Completed NCT00915512 Phase 4 Paliperidone extended-release (ER)
18 A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone Completed NCT01010776 Phase 4 Paliperidone Extended Release (ER)
19 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia Completed NCT00269919 Phase 4 Risperidone Long-Acting Injectable (RLAI)
20 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
21 A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode Completed NCT00378092 Phase 4 Oral risperidone;Risperidone Long-Acting Injection (RLAI);Risperidone Long-Acting Injection (RLAI)
22 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
23 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
24 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
25 Impact of Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
26 Pioglitazone in Patients With Mood Disorders Completed NCT01559857 Phase 4 Pioglitazone;Sugar Pill
27 Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients Completed NCT00223262 Phase 4 Lamotrigine (Drug)
28 An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression Completed NCT00835107 Phase 4 ziprasidone hydrochloride;placebo
29 Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT) Completed NCT00680433 Phase 4 Ketamine;Saline
30 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
31 Dexamethasone and Ketamine on Change of Postoperative Mood Completed NCT03194594 Phase 4 Ketamine Hydrochloride, dexamethasone, and combination of two drugs
32 Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER) Completed NCT01577186 Phase 4 Paliperidone ER
33 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
34 Platelet Rich Plasma (PRP) in Total Knee Replacement Completed NCT00826098 Phase 4
35 Intra-nasal Ketamine for Analgesia in the Emergency Department Completed NCT01686009 Phase 4 Intra-nasal ketamine
36 Effect of Oseltamivir on Cognitive Function in Subjects With Influenza Completed NCT01249833 Phase 4 Oseltamivir
37 Oxytocin and Attachment-related Interpretation Bias Completed NCT02737254 Phase 4 Oxytocin;Placebo
38 Predictors of Antidepressant Response Completed NCT02178696 Phase 4 Celexa or other antidepressant as clinically indicated
39 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
40 Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery Completed NCT02734238 Phase 4 Sesame Oil;testosterone enanthate
41 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
42 Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder Completed NCT00536198 Phase 4 Sertraline;Placebo
43 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
44 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed NCT01382940 Phase 4 rituximab;methotrexate;methylprednisolone;acetaminophen;antihistamine
45 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Completed NCT01331837 Phase 4 Etanercept;Tocilizumab
46 Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders Recruiting NCT02357290 Phase 4 Open-label Treatment with N-Acetylcysteine
47 Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention Recruiting NCT03279952 Phase 4 CNS Stimulant
48 Perimenopausal Effects of Estradiol on Reward Responsiveness Recruiting NCT02255175 Phase 4 Estradiol;Progesterone
49 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
50 Inflammation-Induced CNS Glutamate Changes in Depression Recruiting NCT03004443 Phase 4 Infliximab;Placebo

Search NIH Clinical Center for Pseudobulbar Affect

Genetic Tests for Pseudobulbar Affect

Genetic tests related to Pseudobulbar Affect:

# Genetic test Affiliating Genes
1 Emotional Lability 29

Anatomical Context for Pseudobulbar Affect

MalaCards organs/tissues related to Pseudobulbar Affect:

41
Brain, Spinal Cord, Bone, Lung, Testes, Ovary, Kidney

Publications for Pseudobulbar Affect

Articles related to Pseudobulbar Affect:

(show top 50) (show all 59)
# Title Authors Year
1
Pseudobulbar Affect Due to Skull Base Meningioma Resolving After Temporal Lobectomy for Epilepsy. ( 29747704 )
2018
2
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. ( 29477412 )
2018
3
Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. ( 29505320 )
2018
4
Pseudobulbar Affect in Survivors of Extreme Prematurity With Cerebellar Injury: Support for the Cerebellar Link in Pathologic Laughter and Crying. ( 29961526 )
2018
5
Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction. ( 29092641 )
2018
6
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. ( 29964212 )
2018
7
Correlation between cognitive impairment during the acute phase of first cerebral infarction and development of long-term pseudobulbar affect. ( 29636612 )
2018
8
Pseudobulbar affect as a negative prognostic indicator in amyotrophic lateral sclerosis. ( 29527672 )
2018
9
Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer. ( 28377827 )
2017
10
The Characteristics and Age Effects of Emotional Lability in ADHD Children With and Without Oppositional Defiant Disorder. ( 29224418 )
2017
11
Pseudobulbar Affect: What Nurses, Stroke Survivors, and Caregivers Need to Know. ( 28125430 )
2017
12
Treatment of Pseudobulbar Affect With Fluoxetine and Dextromethorphan in a Woman With Multiple Sclerosis. ( 28691510 )
2017
13
Pharmacotherapeutic management of pseudobulbar affect. ( 29297657 )
2017
14
Introduction to pseudobulbar affect: setting the stage for recognition and familiarity with this challenging disorder. ( 29297656 )
2017
15
Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool. ( 28807457 )
2017
16
Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? ( 27855728 )
2016
17
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. ( 27276999 )
2016
18
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2016
19
Pseudobulbar Affect or Depression in Dementia? ( 26899823 )
2016
20
Cough Suppressant and Fluoxetine in the Treatment of Pseudobulbar Affect: A Case Report. ( 27496344 )
2016
21
Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. ( 27997281 )
2016
22
Behavioral Treatment of Pseudobulbar Affect: A Case Report. ( 27091117 )
2016
23
Recognizing and treating pseudobulbar affect. ( 28044945 )
2016
24
Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). ( 26588919 )
2016
25
Enhancing Approaches to the Identification and Management of Pseudobulbar Affect. ( 27780330 )
2016
26
Prevalence of Pseudobulbar Affect following Stroke: A Systematic Review and Meta-Analysis. ( 26776437 )
2016
27
Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. ( 25420446 )
2015
28
Persistent pseudobulbar affect secondary to acute disseminated encephalomyelitis. ( 25792370 )
2015
29
PSEUDOBULBAR AFFECT IN MULTIPLE SCLEROSIS PATIENTS. ( 26415311 )
2015
30
NueDexta: A Treatment for Pseudobulbar Affect. ( 26735510 )
2015
31
Identification of pseudobulbar affect symptoms in Veterans with possible traumatic brain injury. ( 26744849 )
2015
32
Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment Options. ( 26693049 )
2015
33
Association of Pseudobulbar Affect symptoms with quality of life and healthcare costs in Veterans with traumatic brain injury. ( 26519634 )
2015
34
Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents. ( 26526856 )
2015
35
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. ( 26471212 )
2015
36
Diagnosing pseudobulbar affect in traumatic brain injury. ( 25336956 )
2014
37
Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review. ( 24916672 )
2014
38
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. ( 25061302 )
2014
39
Information/education page. Pseudobulbar affect. ( 25064417 )
2014
40
Dextromethorphan/quinidine for the treatment of pseudobulbar affect. ( 24704895 )
2014
41
Review of Dextromethorphan 20A mg/Quinidine 10A mg (NUEDEXTA(Ar)) for Pseudobulbar Affect. ( 26000221 )
2014
42
Nuedexta for the Treatment of Pseudobulbar Affect: Estimating the Financial Impact to the Scottish NHS. ( 27200929 )
2014
43
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. ( 25062507 )
2014
44
Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders. ( 25008395 )
2014
45
PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. ( 23991068 )
2013
46
Clinical, behavioral, and treatment differences in nursing facility residents with dementia, with and without pseudobulbar affect symptomatology. ( 24217191 )
2013
47
Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing. ( 23946627 )
2013
48
Pseudobulbar affect: prevalence and management. ( 24348042 )
2013
49
Chemotherapy-induced pseudobulbar affect: a novel case. ( 24247870 )
2013
50
Memantine may affect pseudobulbar affect in patients with Alzheimer's disease. ( 25287877 )
2013

Variations for Pseudobulbar Affect

ClinVar genetic disease variations for Pseudobulbar Affect:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
2 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic

Expression for Pseudobulbar Affect

Search GEO for disease gene expression data for Pseudobulbar Affect.

Pathways for Pseudobulbar Affect

GO Terms for Pseudobulbar Affect

Sources for Pseudobulbar Affect

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....